• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多模式偏头痛管理与对偏头痛缓解的追求:一项叙述性综述

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review.

作者信息

Blumenfeld Andrew M, Lipton Richard B, Silberstein Stephen, Tepper Stewart J, Charleston Larry, Landy Stephen, Kuruvilla Deena E, Manack Adams Aubrey

机构信息

The Los Angeles and San Diego Headache Centers, San Diego, CA, USA.

Albert Einstein College of Medicine, Bronx, NY, USA.

出版信息

Neurol Ther. 2023 Oct;12(5):1533-1551. doi: 10.1007/s40120-023-00529-x. Epub 2023 Aug 5.

DOI:10.1007/s40120-023-00529-x
PMID:37542624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10444724/
Abstract

Migraine is a neurologic disease with a complex pathophysiology that can be controlled with current treatment options but not cured. Therefore, treatment expectations are highly variable. The concept of migraine freedom was recently introduced and can mean different things, with some, for example, expecting complete freedom from headache and associated symptoms and others accepting the occasional migraine attack if it does not impact functioning. Therefore, migraine management should be optimized so that patients can have the best opportunity to achieve their optimal treatment goals. With migraine freedom as a goal and, given the complex pathophysiology of migraine and the high incidence of comorbidities among individuals with migraine, treatment with a single modality may be insufficient, as it may not achieve migraine freedom in those with more frequent or disabling attacks. In this clinical perspective article, we have identified four key, partially overlapping principles of multimodal migraine treatment: (1) manage common comorbidities; (2) control modifiable risk factors for progression by addressing medication and caffeine overuse; (3) diagnose and treat secondary causes of headache, if present; and (4) individualize acute and preventive treatments to minimize pain, functional disability, and allodynia. There are many barriers to pursuing migraine freedom, and strategies to overcome them should be optimized. Migraine freedom should be an aspirational goal both at the individual attack level and for the disease overall. We believe that a comprehensive and multimodal approach that addresses all barriers people with migraine face could move patients closer to migraine freedom.

摘要

偏头痛是一种具有复杂病理生理学机制的神经系统疾病,目前的治疗方法可以控制病情,但无法治愈。因此,治疗期望差异很大。最近引入了偏头痛缓解的概念,其含义可能各不相同,例如,有些人期望完全摆脱头痛及相关症状,而另一些人则认为如果偏头痛发作不影响功能,偶尔发作也可接受。因此,应优化偏头痛管理,以便患者有最佳机会实现其最佳治疗目标。以偏头痛缓解为目标,鉴于偏头痛复杂的病理生理学机制以及偏头痛患者中合并症的高发生率,单一治疗方式可能并不充分,因为对于发作更频繁或致残的患者,单一治疗方式可能无法实现偏头痛缓解。在这篇临床观点文章中,我们确定了多模式偏头痛治疗的四个关键且部分重叠的原则:(1)管理常见合并症;(2)通过解决药物和咖啡因过度使用问题来控制可改变的病情进展风险因素;(3)诊断并治疗头痛的继发原因(如果存在);(4)个体化急性和预防性治疗,以尽量减少疼痛、功能障碍和痛觉过敏。实现偏头痛缓解存在许多障碍,应优化克服这些障碍的策略。偏头痛缓解应成为个体发作层面以及整个疾病的理想目标。我们认为,一种全面的多模式方法,能够解决偏头痛患者面临的所有障碍,可以使患者更接近偏头痛缓解的目标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b948/10444724/2d19ac775aa9/40120_2023_529_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b948/10444724/0f18d680e61a/40120_2023_529_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b948/10444724/62a52d3165d4/40120_2023_529_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b948/10444724/2d19ac775aa9/40120_2023_529_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b948/10444724/0f18d680e61a/40120_2023_529_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b948/10444724/62a52d3165d4/40120_2023_529_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b948/10444724/2d19ac775aa9/40120_2023_529_Fig3_HTML.jpg

相似文献

1
Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review.多模式偏头痛管理与对偏头痛缓解的追求:一项叙述性综述
Neurol Ther. 2023 Oct;12(5):1533-1551. doi: 10.1007/s40120-023-00529-x. Epub 2023 Aug 5.
2
Risk factors for migraine disease progression: a narrative review for a patient-centered approach.偏头痛疾病进展的风险因素:以患者为中心的方法进行叙述性综述。
J Neurol. 2023 Dec;270(12):5692-5710. doi: 10.1007/s00415-023-11880-2. Epub 2023 Aug 24.
3
Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study.预测急性偏头痛药物治疗反应不足:来自美国偏头痛患病率和预防(AMPP)研究的结果。
Headache. 2016 Nov;56(10):1635-1648. doi: 10.1111/head.12941. Epub 2016 Oct 12.
4
Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.加巴喷丁在偏头痛预防性治疗中的疗效和安全性:叙述性综述。
Adv Ther. 2020 May;37(5):2034-2049. doi: 10.1007/s12325-020-01319-9. Epub 2020 Apr 21.
5
Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme.与日本偏头痛急性治疗反应不足相关的因素:来自 Adelphi 偏头痛疾病特定项目的真实世界数据的分析。
BMC Neurol. 2020 Jul 8;20(1):274. doi: 10.1186/s12883-020-01848-4.
6
SumaRT/Nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study.苏玛特/那普 vs 萘普生钠治疗偏头痛及疾病修饰作用的初步研究。
Headache. 2014 Jan;54(1):67-79. doi: 10.1111/head.12211. Epub 2013 Sep 10.
7
Tackling chronic migraine: current perspectives.应对慢性偏头痛:当前观点
J Pain Res. 2014 Apr 8;7:185-94. doi: 10.2147/JPR.S61819. eCollection 2014.
8
Migraine Progression: A Systematic Review.偏头痛进展:系统评价。
Headache. 2019 Mar;59(3):306-338. doi: 10.1111/head.13459. Epub 2018 Dec 27.
9
A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN.无疼痛、偏头痛相关功能障碍和其他结局的密切关联:随机 lasmiditan 研究 SAMURAI 和 SPARTAN 的事后分析结果。
J Headache Pain. 2021 Aug 28;22(1):101. doi: 10.1186/s10194-021-01303-w.
10
Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study.2017 年美国偏头痛症状和治疗研究中的未满足急性治疗需求。
Headache. 2019 Sep;59(8):1310-1323. doi: 10.1111/head.13588. Epub 2019 Aug 13.

引用本文的文献

1
Integrating manual therapy into headache management: bridging the evidence gap.将手法治疗纳入头痛管理:弥合证据差距。
Neurol Sci. 2025 Jul;46(7):3287-3289. doi: 10.1007/s10072-025-08093-y. Epub 2025 Mar 12.
2
Eptinezumab treatment was associated with longer interictal headache/migraine periods which corresponded to greater improvements in patient-reported quality of life measures.艾普奈珠单抗治疗与更长的发作间期头痛/偏头痛期相关,这与患者报告的生活质量指标的更大改善相对应。
J Neurol. 2024 Dec 12;272(1):4. doi: 10.1007/s00415-024-12809-z.
3
A post hoc analysis of migraine-associated symptoms from the phase 3 randomized, double-blind, sham-controlled Trial of External trigeminal nerve stimulation for the Acute treatment of Migraine (TEAM) study.

本文引用的文献

1
Migraine treatment with external concurrent occipital and trigeminal neurostimulation-A randomized controlled trial.偏头痛的外部并发枕神经和三叉神经刺激治疗:一项随机对照试验。
Headache. 2022 Sep;62(8):989-1001. doi: 10.1111/head.14350. Epub 2022 Jun 24.
2
Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study.用于预测非处方急性偏头痛药物治疗反应的预测模型:来自美国偏头痛患病率和预防研究的结果。
Headache. 2022 Jun;62(6):755-765. doi: 10.1111/head.14312. Epub 2022 May 11.
3
Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.
一项针对偏头痛相关症状的事后分析,该分析来自用于偏头痛急性治疗的三叉神经外刺激3期随机、双盲、假对照试验(TEAM)研究。
Headache. 2025 May;65(5):779-790. doi: 10.1111/head.14860. Epub 2024 Nov 27.
4
What Is Combination Treatment in Migraine? Moving Toward a Uniform Definition of a Familiar Principle.偏头痛的联合治疗是什么?迈向对一个熟悉原则的统一界定。
Neurol Ther. 2024 Dec;13(6):1535-1540. doi: 10.1007/s40120-024-00669-8. Epub 2024 Oct 15.
5
Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review.阿托格潘与肉毒杆菌毒素A联合用于慢性偏头痛预防性治疗的安全性和有效性的真实世界证据:一项回顾性病历审查。
Pain Ther. 2024 Dec;13(6):1571-1587. doi: 10.1007/s40122-024-00649-8. Epub 2024 Sep 17.
6
Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety.抗降钙素基因相关肽/降钙素基因相关肽受体单克隆抗体与A型肉毒毒素联合应用作为难治性慢性偏头痛的一种新型治疗方法:真实世界临床证据的回顾性研究及一项双盲、随机临床试验方案以确定其疗效和安全性
Front Pharmacol. 2023 Dec 13;14:1296577. doi: 10.3389/fphar.2023.1296577. eCollection 2023.
阿替利珠单抗 - 一种口服 CGRP 拮抗剂 - 通过 CSD 减弱脑膜伤害感受器的激活。
Cephalalgia. 2022 Aug;42(9):933-943. doi: 10.1177/03331024221083544. Epub 2022 Mar 25.
4
Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine.降钙素基因相关肽(CGRP)单克隆抗体与A型肉毒毒素联合治疗慢性偏头痛的预防性治疗
Headache. 2022 Jan;62(1):106-108. doi: 10.1111/head.14244. Epub 2021 Dec 7.
5
Dissecting the shared genetic basis of migraine and mental disorders using novel statistical tools.利用新型统计工具剖析偏头痛与精神障碍的共有遗传基础。
Brain. 2022 Mar 29;145(1):142-153. doi: 10.1093/brain/awab267.
6
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.美国头痛学会共识声明:更新将新的偏头痛治疗方法整合到临床实践中的建议。
Headache. 2021 Jul;61(7):1021-1039. doi: 10.1111/head.14153. Epub 2021 Jun 23.
7
Efficacy of erenumab in chronic migraine patients with and without ictal allodynia.依瑞奈尤单抗治疗伴有和不伴有发作性触诱发痛的慢性偏头痛患者的疗效。
Cephalalgia. 2021 Oct;41(11-12):1152-1160. doi: 10.1177/03331024211010305. Epub 2021 May 13.
8
Exploring the Hereditary Nature of Migraine.探索偏头痛的遗传本质。
Neuropsychiatr Dis Treat. 2021 Apr 22;17:1183-1194. doi: 10.2147/NDT.S282562. eCollection 2021.
9
Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine.降钙素基因相关肽靶向单克隆抗体药物作为依替巴肽治疗慢性偏头痛患者的附加疗法的疗效和耐受性。
Pain Med. 2021 Aug 6;22(8):1857-1863. doi: 10.1093/pm/pnab093.
10
Non-Pharmacological Approaches to Headaches: Non-Invasive Neuromodulation, Nutraceuticals, and Behavioral Approaches.非药物性头痛治疗方法:非侵入性神经调节、营养保健品和行为方法。
Int J Environ Res Public Health. 2021 Feb 5;18(4):1503. doi: 10.3390/ijerph18041503.